Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer

Abstract

The 13q21 tumor suppressor locus, as defined by chromosomal deletion, harbors the KLF5 transcription factor which may have tumor suppressor function. To investigate whether KLF5 plays a role in breast cancer, we evaluated all genes and/or expressed sequence tags (ESTs) within a 3.3 Mb common region of deletion at 13q21. Of these, only KLF5 mRNA was expressed at high levels in non-neoplastic breast epithelial cells and in normal human mammary tissue, but at lower levels in various breast cancer cell lines. Using the real time TaqMan PCR assay, hemizygous deletion at KLF5 was detected in 13 out of 30, or 43% of breast cancer cell lines tested, and various degrees of loss of expression were detected in 21 out of 30, or 70% of these cell lines. Each of the cases with hemizygous deletion also exhibited loss of KLF5 expression, suggesting that loss of expression can result from chromosomal deletion, and that KLF5 may undergo haploinsufficiency during carcinogenesis. Only one of the 30 breast cancer cell lines tested exhibited a mutation in KLF5, and neither promoter methylation nor homozygous deletion was detected in any of the cell lines. In contrast, loss of heterozygosity (LOH) was frequently detected at KLF5. Re-expression of wild-type KLF5 in T-47D breast cancer cells significantly inhibited colony formation in these cells. Of the KLF5-transfected clones that did form colonies, none were found to express KLF5 mRNA. These findings suggest that loss of function by deletion and/or loss of expression frequently occurs at KLF5, and KLF5 suppresses tumor cell growth in breast cancer.

Oncogene (2002) 21, 6567–6572. doi:10.1038/sj.onc.1205817

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Black AR, Black JD, Azizkhan-Clifford J . 2001 J. Cell. Physiol. 188: 143–160

  • Chen C, Brabham WW, Stultz BG, Frierson HFJ, Barrett JC, Sawyers CL, Isaacs JT, Dong JT . 2001 Genes Chromosomes Cancer 31: 333–344

  • Conkright MD, Wani MA, Anderson KP, Lingrel JB . 1999 Nucleic Acids Res. 27: 1263–1270

  • Dang DT, Pevsner J, Wang VW . 2000 Int. J. Biochem. Cell Biol. 32: 1103–1121

  • Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP . 1998 Nat. Genet. 19: 348–355

  • Dong JT, Chen C, Stultz BG, Isaacs JT, Frierson Jr HF . 2000 Cancer Res. 60: 3880–3883

  • Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ . 1998 Nature 396: 177–180

  • Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB . 1996 Proc. Natl. Acad. Sci. USA 93: 9821–9826

  • Hyytinen ER, Frierson HF, Boyd JC, Chung LWK, Dong JT . 1999 Genes Chromosomes Cancer 25: 108–114

  • Kainu T, Juo SH, Desper R, Schaffer AA, Gillanders E, Rozenblum E, Freas-Lutz D, Weaver D, Stephan D, Bailey-Wilson J, Kallioniemi OP, Tirkkonen M, Syrjakoski K, Kuukasjarvi T, Koivisto P, Karhu R, Holli K, Arason A, Johannesdottir G, Bergthorsson JT, Johannsdottir H, Egilsson V, Barkardottir RB, Johannsson O, Haraldsson K, Sandberg T, Holmberg E, Gronberg H, Olsson H, Borg A, Vehmanen P, Eerola H, Heikkila P, Pyrhonen S, Nevanlinna H . 2000 Proc. Natl. Acad. Sci. USA 97: 9603–9608

  • Knuutila S, Aalto Y, Autio K, Bjorkqvist AM, El-Rifai W, Hemmer S, Huhta T, Kettunen E, Kiuru-Kuhlefelt S, Larramendy ML, Lushnikova T, Monni O, Pere H, Tapper J, Tarkkanen M, Varis A, Wasenius VM, Wolf M, Zhu Y . 1999 Am. J. Pathol. 155: 683–694

  • Knuutila S, Bjorkqvist AM, Autio K, Tarkkanen M, Wolf M, Monni O, Szymanska J, Larramendy ML, Tapper J, Pere H, El-Rifai W, Hemmer S, Wasenius VM, Vidgren V, Zhu Y . 1998 Am. J. Pathol. 152: 1107–1123

  • Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC, Glucksman MJ, Narla J, Eng FJ, Chan AM, Ferrari AC, Martignetti JA, Friedman SL . 2001 Science 294: 2563–2566

  • Roylance R, Gorman P, Harris W, Liebmann R, Barnes D, Hanby A, Sheer D . 1999 Cancer Res. 59: 1433–1436

  • Rozenblum E, Vahteristo P, Sandberg T, Bergthorsson JT, Syrjakoski K, Weaver D, Haraldsson K, Johannsdottir HK, Vehmanen P, Nigam S, Golberger N, Robbins C, Pak E, Dutra A, Gillander E, Stephan DA, Bailey-Wilson J, Juo SH, Kainu T, Arason A, Barkardottir RB, Nevanlinna H, Borg A, Kallioniemi OP . 2002 Hum. Genet. 110: 111–121

  • Shi H, Zhang Z, Wang X, Liu S, Teng CT . 1999 Nucleic Acids Res. 27: 4807–4815

  • Tirkkonen M, Johannsson O, Agnarsson BA, Olsson H, Ingvarsson S, Karhu R, Tanner M, Isola J, Barkardottir RB, Borg A, Kallioniemi OP . 1997 Cancer Res. 57: 1222–1227

  • Ton-That H, Kaestner KH, Shields JM, Mahatanankoon CS, Yang VW . 1997 FEBS Lett. 419: 239–243

Download references

Acknowledgements

This study was supported in part by NIH grants CA85560 and CA87921 from the National Cancer Institute.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jin-Tang Dong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, C., Bhalala, H., Qiao, H. et al. A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer. Oncogene 21, 6567–6572 (2002). https://doi.org/10.1038/sj.onc.1205817

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205817

Keywords

This article is cited by

Search

Quick links